Want to see FR:ALSEN full AI Analyst Report?
Top Page
Sensorion SAS
(ALSEN)
Select Model
Select Model
Rating:44Neutral
Price Target:
€0.24
▼(-10.74% Downside)
Action:Reiterated
Date:07/30/26
The score is primarily weighed down by weak financial performance—zero revenue in 2025, large ongoing losses, and sustained cash burn—despite relatively low leverage. Technicals are also unfavorable, with the price below key longer-term moving averages, while valuation provides limited support due to negative earnings and no dividend data.
Positive Factors
Low Leverage
Low leverage gives Sensorion more financial flexibility than a heavily indebted development-stage biotech. Modest debt reduces fixed repayment pressure and leaves greater scope to direct available resources toward clinical programs, although it does not eliminate the need for future funding.
Negative Factors
Zero Recent Revenue
The complete loss of annual revenue in 2025 materially weakens visibility into Sensorion’s operating model and indicates that prior income was not yet recurring or dependable. Without established product sales, future funding remains tied to collaborations, licensing, grants, or capital raising.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Low leverage gives Sensorion more financial flexibility than a heavily indebted development-stage biotech. Modest debt reduces fixed repayment pressure and leaves greater scope to direct available resources toward clinical programs, although it does not eliminate the need for future funding.
Read all positive factors
Sensorion SAS (ALSEN) vs. iShares MSCI France ETF (EWQ)
Market Cap
€128.09M
Dividend YieldN/A
Average Volume (3M)941.83K
Price to Earnings (P/E)―
Beta (1Y)0.74
Revenue GrowthN/A
EPS Growth-5.60%
CountryFR
Employees63
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.10
Shares Outstanding515,648,600
10 Day Avg. Volume585,849
30 Day Avg. Volume941,832
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)2.28
Price to Sales (P/S)0.00
P/FCF Ratio-3.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.00Price Target Upside270.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€21.86M
Sensorion SAS Business Overview & Revenue Model
Company Description
Sensorion SA is a clinical-stage biopharmaceutical firm based in Montpellier, France, specializing in the development of therapies for inner ear disorders. Their key initiatives include gene therapy programs: OTOF-GT, designed to restore hearing f...
How the Company Makes Money
Sensorion primarily makes money through (1) collaboration and licensing arrangements and (2) external funding mechanisms typical of R&D-stage biopharma, rather than recurring product sales.
1) Collaboration and licensing revenue: The company can ...
Sensorion SAS Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 6.65M | 5.70M | 4.93M | 4.26M |
| Gross Profit | -1.36M | 6.65M | 3.79M | 4.16M | 3.75M |
| EBITDA | -35.21M | -27.58M | -21.33M | -22.44M | -17.46M |
| Net Income | -29.43M | -25.97M | -22.06M | -23.21M | -15.14M |
Balance Sheet | |||||
| Total Assets | 57.89M | 89.28M | 46.50M | 38.93M | 59.02M |
| Cash, Cash Equivalents and Short-Term Investments | 47.46M | 76.98M | 36.97M | 26.20M | 50.00M |
| Total Debt | 1.28M | 2.20M | 2.87M | 3.76M | 3.99M |
| Total Liabilities | 13.41M | 17.14M | 13.23M | 17.06M | 15.03M |
| Stockholders Equity | 44.48M | 72.14M | 33.27M | 21.87M | 43.98M |
Cash Flow | |||||
| Free Cash Flow | -27.64M | -22.45M | -21.94M | -22.92M | -11.81M |
| Operating Cash Flow | -27.39M | -21.33M | -21.07M | -21.41M | -10.77M |
| Investing Cash Flow | 9.24M | -11.13M | -381.06K | -1.54M | -1.07M |
| Financing Cash Flow | -1.16M | 62.26M | 32.20M | -820.68K | -715.07K |
Sensorion SAS Technical Analysis
Negative
0.27
Price Trends
0.27
Negative
0.31
Negative
0.34
Negative
Market Momentum
>-0.01
Positive
32.53
Neutral
15.43
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALSEN, the sentiment is Negative. The current price of 0.27 is below the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.27, and below the 200-day MA of 0.34, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 32.53 is Neutral, neither overbought nor oversold. The STOCH value of 15.43 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALSEN.
Sensorion SAS Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | €818.71M | -25.05 | ― | ― | -23.21% | -50.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | €202.80M | -4.98 | -94.14% | ― | -5.98% | -8.67% | |
47 Neutral | €239.88M | -3.32 | -63.53% | ― | 291.43% | 12.24% | |
46 Neutral | €24.92M | -1.31 | 42.20% | ― | -99.93% | 44.53% | |
44 Neutral | €128.09M | -2.54 | -58.01% | ― | ― | -5.60% |
* Healthcare Sector Average
FR:ALSEN
Sensorion SAS
0.25
-0.05
-17.88%
FR:ALCOX
Nicox SA
0.38
0.05
13.73%
FR:TNG
Transgene
0.86
-0.23
-20.92%
FR:SIGHT
GenSight Biologics SA
0.11
-0.04
-29.33%
FR:ALCLS
Cellectis SA
2.80
0.38
15.87%
FR:MEDCL
MedinCell SA
22.80
4.79
26.60%
Sensorion SAS Corporate Events
Sensorion Wins Fast-Track French Approval for First SENS-601 Gene Therapy Trial
Sep 3, 2026
Sensorion has secured authorization from France’s ANSM, via a Fast Track procedure, to launch HearConnex, a Phase I/II trial of its lead gene therapy SENS-601 for GJB2 gene-related congenital deafness, with the first patient dosing targeted ...
Sensorion Launches Technical Reverse Stock Split on Euronext Growth
Jul 29, 2026
Sensorion has announced a technical reverse stock split of its shares on Euronext Growth Paris, consolidating 50 existing shares with a nominal value of €0.10 into 1 new share with a nominal value of €5, without altering the total shar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.